전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved188 programs
AntibodyLimited DatastaleJiangsu HengruiPhase 2

Camrelizumab+cetuximab+chemotherapy (Camrelizumab+cetuximab+chemotherapy)

Squamous Cell Carcinoma of Head and Neck · Squamous Cell Carcinoma of Head and Neck

#SquamousCellCarcinomaofHeadandNe#Antibody#Phase2#monoclonal-antibody#Jiangsu
Trials 1Status Active
CGTLimited DatastaleCaribou Biosciences, Inc.Preclinical

Caribou-sponsored investigational therapy (Caribou-sponsored investigational therapy)

Lymphoma, Non-Hodgkin; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleHangzhou Suxi Biopharmaceutical…Phase 2

Chidamide Combined with NKG2D CAR-NK Cell Therapy (Chidamide Combined with NKG2D CAR-NK Cell Therapy)

HIV (Human Immunodeficiency Virus) · HIV (Human Immunodeficiency Virus)

#HIVHumanImmunodeficiencyVirus#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleJennifer Crombie, MDPhase 2

Chimeric Antigen Receptor (CAR, Chimeric Antigen Receptor, Chimeric Antigen Receptor (CAR) Therapy Infusion)

Primary Mediastinal Large B-cell Lymphoma (PMBCL); Primary Mediastinal Large B Cell Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleUniversitätsklinikum KölnPhase 2

Nivolumab/Ipilimumab (Concurrent Chemo-radio-immunotherapy, Concurrent Chemo-radio-immunotherapy (Nivolumab/Ipilimumab))

Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases · Cervical Cancer ≥ FIGO IIB and or Lymph

#CervicalCancerFIGOIIBandorLymph#Antibody#Phase2#monoclonal-antibody#CervicalCancerFIGOIIBandorLymphN+1
Trials 1Status Discontinued
AntibodyLimited DatastaleFudan UniversityPreclinical

DEBIRI Combined With Chemotherapy and Bevacizumab (DEBIRI Combined With Chemotherapy and Bevacizumab)

Colorectal Neoplasms · Colorectal Neoplasms

#ColorectalNeoplasms#Antibody#Preclinical#monoclonal-antibody#Fudan
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Radiotherapy)

HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-expressingHigh-riskorVeryHi+1
Trials 1Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with fruquintinib and Tislelizumab)

HER2-positive Gastric Cancer; Immunotherapy · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveGastricCancer+2
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab vedotin + Sintilimab + Multimodality radiotherapy)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveAdvancedGastricCanc+1
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy (Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy)

B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleQilu Hospital of Shandong Unive…Preclinical

Doublet or triplet chemotherapy combined with cetuximab (Doublet or triplet chemotherapy combined with cetuximab)

Colon Cancer · Colon Cancer

#ColonCancer#Antibody#Preclinical#monoclonal-antibody#Qilu
Trials 1Status Active
CGTLimited DatastaleSinobioway Cell Therapy Co., Lt…Preclinical

EPCAM-targeted CAR-T cells (EPCAM-targeted CAR-T cells)

Stomach Neoplasms · Liver Neoplasms

#LiverNeoplasms#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 3

trastuzumab (Herceptin, Endocrine therapy combined with trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase3#monoclonal-antibody#Sun
Trials 1Status Active
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

FL33-03 CAR-T therapy (FL33-03 CAR-T therapy)

Refractory/Relapsed Acute Myeloid Leukaemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMinicirclePhase 1

Follistatin and klotho gene therapy (Follistatin and klotho gene therapy)

Healthy Adults · Healthy Adults

#HealthyAdults#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleFuda Cancer Hospital, GuangzhouPhase 2

GD2 CAR-T immunotherapy (GD2 CAR-T immunotherapy)

Glioma of Brain; CAR-T Cell Immunotherapy · GD2

#GD2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleSinobioway Cell Therapy Co., Lt…Preclinical

GD2-targeted CAR-T cells (GD2-targeted CAR-T cells)

Relapsed or Refractory Neuroblastoma · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleLakefront Biotherapeutics NVPhase 3

GLPG CAR T-cell therapy (GLPG CAR T-cell therapy)

Hematological Malignancies · Hematological Malignancies

#HematologicalMalignancies#CGT#Phase3#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital of G…Phase 1

GPC3 and/or TGFβ targeting CAR-T cells (GPC3 and/or TGFβ targeting CAR-T cells)

Hepatocellular Carcinoma; Immunotherapy · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleInstitut National de la Santé E…Phase 1

Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes (Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes)

Pancreatic Adenocarcinoma · Pancreatic Adenocarcinoma

#PancreaticAdenocarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active

6 / 10 pages

← PreviousNext →